8-K: Intelligent Bio Solutions Reports Record Q2 Revenue, 48% Growth

Intelligent Bio Solutions Inc. announced record fiscal second quarter revenue growth of 48% year-over-year, driven by a 104% surge in reader sales and a 33% increase in cartridge sales.

Summary

• Record fiscal second quarter revenue reached $896,774, marking a 48% increase year-over-year.
• First half fiscal 2026 revenue surpassed $2 million, up 36% year-over-year.
• Reader sales more than doubled, increasing 104% year-over-year to $246,519 for the second quarter.
• Cartridge sales grew 33% year-over-year to $516,754 for the second quarter.
• Gross profit margins for the first half of fiscal 2026 increased 10% year-over-year to 49%.
• Current assets stood at $12.17 million as of December 31, 2025, including a $9.40 million receivable from a private placement.
• Closed a $10.0 million private placement, with net proceeds of $9.40 million received on January 2, 2026, intended for working capital, FDA 510(k) submission, and international expansion.
• Initiated additional clinical studies for FDA 510(k) submission to enter the U.S. market beyond the Forensic Use Only category.
• Announced a new manufacturing partnership expected to improve gross profit margins and drive cost efficiencies.
• Formed a strategic alliance with Vlepis Pty Ltd to enter the consumer health monitoring market.
• Secured a major contract with a leading industrial service provider.
• Net loss for Q2 FY26 was $(2,686,613), compared to $(2,256,797) in Q2 FY25.
• Net loss per share for Q2 FY26 was $(2.82), compared to $(4.96) in Q2 FY25 (adjusted for reverse stock split).

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, driven by significant revenue growth, expanding market penetration, improved gross margins, and a successful capital raise that strengthens the balance sheet and funds critical regulatory and expansion initiatives. While net losses persist, the underlying operational metrics and strategic advancements are highly encouraging.

Positives

• Record fiscal second quarter revenue of $896,774, representing a 48% year-over-year increase.
• First half fiscal 2026 revenue exceeded $2 million, up 36% year-over-year.
• Reader sales surged 104% year-over-year in Q2 FY26, demonstrating strong market demand and expanding the installed base.
• Cartridge sales grew 33% year-over-year in Q2 FY26, confirming active customer usage and reordering of consumables.
• Gross profit margins for the first half of fiscal 2026 increased by 10% year-over-year to 49%, reflecting improved operational efficiency.
• Strong balance sheet capitalization with $12.17 million in current assets as of December 31, 2025, including $9.40 million from a private placement.
• Successful closing of a $10.0 million private placement, providing $9.40 million in net proceeds for strategic initiatives.
• Initiation of additional clinical studies for FDA 510(k) submission, paving the way for U.S. market entry beyond Forensic Use Only.
• New manufacturing partnership expected to enhance gross profit margins and production cost efficiencies.
• Strategic alliance with Vlepis Pty Ltd opens new revenue opportunities in the fast-growing consumer health monitoring market.
• Secured a major contract with a leading industrial service provider, expanding market presence.
• Added 49 new customer accounts in the first half of fiscal 2026, indicating sustained customer adoption.
• Net loss per share improved to $(2.82) in Q2 FY26 from $(4.96) in Q2 FY25, and to $(6.27) in H1 FY26 from $(11.82) in H1 FY25 (adjusted for reverse stock split).

Negatives

• Net loss increased to $(2,686,613) for the three months ended December 31, 2025, compared to $(2,256,797) for the same period in 2024.
• Net loss for the six months ended December 31, 2025, increased to $(5,681,605), compared to $(4,951,596) for the same period in 2024.
• Selling, general and administrative expenses increased to $(2,337,041) in Q2 FY26 from $(1,809,114) in Q2 FY25, and to $(4,996,865) in H1 FY26 from $(3,758,130) in H1 FY25.
• Cash and cash equivalents decreased to $740,371 as of December 31, 2025, from $1,019,909 as of June 30, 2025.
• Total liabilities increased to $6,763,231 as of December 31, 2025, from $5,435,962 as of June 30, 2025.

Risks

• Ability to successfully develop and commercialize drug and diagnostic tests.
• Ability to realize commercial benefits from partnerships and collaborations.
• Ability to secure regulatory clearance or approvals, particularly for FDA 510(k) submission.
• Known and unknown risks, uncertainties, and other factors described in public filings with the U.S. Securities and Exchange Commission.

Future Outlook

The company is building sustainable momentum as it advances its regulatory pathway toward planned U.S. market entry, beyond the Forensic Use Only category. It intends to use the proceeds from the private placement to fund its 510(k) submission with the FDA and further international market expansion. Management believes the second quarter's reader installation surge will drive sustained cartridge demand in future periods. The new manufacturing partnership is expected to improve gross profit margins and drive cost efficiencies as production volumes scale.

Management Comments

• "Our second quarter figures demonstrate consistency and solid progress across our business." Harry Simeonidis, President and CEO.
• "Reader sales more than doubling shows market demand for our non-invasive fingerprint drug testing technology and significantly expands our installed base, the engine for future recurring revenue." Harry Simeonidis, President and CEO.
• "Equally important is the 33% growth in cartridge sales, which confirms existing customers are actively using our system and reordering consumables." Harry Simeonidis, President and CEO.
• "This is our razor-razorblade model working as designed hardware placements create the foundation, and consumable sales deliver ongoing revenue." Harry Simeonidis, President and CEO.
• "With strong year-over-year growth and first-half revenue exceeding $2 million, we're building sustainable momentum as we advance our regulatory pathway toward planned U.S. market entry." Harry Simeonidis, President and CEO.
• "We are seeing the financial model take shape as intended." Spiro Sakiris, CFO.
• "104% reader growth in fiscal Q2 is building our installed base, while 33% cartridge growth shows our recurring revenue model gaining traction." Spiro Sakiris, CFO.
• "These achievements are the result of deliberate, strategic marketing investment aimed at enhancing our market awareness." Spiro Sakiris, CFO.
• "Our operating expense control and revenue scaling are creating the operational leverage we've been targeting." Spiro Sakiris, CFO.
• "This is complemented by the $9.40 million net proceeds from the private placement of our securities, which funds were received on January 2, 2026, and strongly capitalized our balance sheet." Spiro Sakiris, CFO.
• "We're investing in commercial expansion linked to results while maintaining financial discipline a balance we believe will serve us well through fiscal 2026." Spiro Sakiris, CFO.

Industry Context

StockSavvy.ai notes that Intelligent Bio Solutions operates in the rapidly evolving medical technology sector, specifically targeting non-invasive, rapid drug screening. The company's focus on fingerprint sweat analysis positions it uniquely against traditional methods, addressing growing demands for privacy, dignity, and operational efficiency in workplace drug testing. The strategic alliance with Vlepis Pty Ltd to enter the consumer health monitoring market indicates a broader ambition to diversify beyond commercial screening, aligning with the increasing trend of B2B2C and direct-to-consumer health solutions. The pursuit of FDA 510(k) submission is critical for unlocking the substantial U.S. market, a common strategic move for med-tech companies seeking significant growth.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against. However, the reported revenue growth rates (48% for Q2, 36% for H1) and gross profit margin improvement (10% increase to 49%) suggest strong performance within the niche of non-invasive drug screening, especially given the expansion into 27 countries and 49 new customer accounts in H1 FY26. Without direct industry benchmarks, it is difficult to definitively state how these compare to specific competitors, but the growth trajectory is indicative of successful market penetration for a specialized medical technology.

Stakeholder Impact

• Shareholders: Potentially positive due to strong revenue growth, improved gross margins, strategic partnerships, and a strengthened balance sheet from the capital raise, which could lead to future value creation. The reverse stock split might also be seen as a move to improve share price perception and Nasdaq compliance.
• Employees: Potential for growth and expansion as the company scales operations, enters new markets, and develops new products.
• Customers: Benefit from expanding availability of non-invasive drug screening technology, improved operational efficiency, and potentially new consumer health monitoring solutions.
• Creditors: Improved financial stability and capitalization from the private placement could reduce credit risk.

Next Steps

• Continue additional clinical studies for FDA 510(k) submission.
• Progress through the regulatory pathway for planned U.S. market entry beyond Forensic Use Only.
• Leverage the new manufacturing partnership to improve gross profit margins and drive cost efficiencies.
• Further international market expansion.
• Develop and commercialize solutions for the consumer health monitoring market through the alliance with Vlepis Pty Ltd.
• Drive sustained cartridge demand from the growing installed base of readers.

Key Dates

Recommendation

The filing demonstrates robust operational momentum with significant year-over-year revenue growth, particularly in reader sales, which underpins the company's "razor-razorblade" recurring revenue model. The substantial improvement in gross profit margins, successful capital raise, and clear strategic pathway towards FDA approval for the lucrative U.S. market are strong indicators of future growth potential. While the company is still operating at a net loss, the positive trends in key operational metrics and strategic initiatives suggest a strong trajectory for long-term value creation, making it an attractive investment for growth-oriented investors.

Keywords

Intelligent Bio Solutions, INBS, Financial Results, Q2 2026, Revenue Growth, Fingerprint Drug Testing, Non-invasive Testing, Medical Technology, FDA 510(k), Private Placement, Gross Profit Margin, Drug Screening, Biotechnology, Healthcare, Nasdaq